Hidradenitis Suppurativa clinical trials at UC Health

• A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

  open to all eligible people

  TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

  at UC Irvine UCSD

• Clinical and Biological Characteristics of Hidradenitis Suppurativa

  open to eligible people ages 13 years and up

  Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

  at UCSF

• Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

  open to eligible people ages 10 years and up

  Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

  at UCSF

• Experimental Risankizumab vs. Placebo For Moderate to Severe Hidradenitis Suppurativa (painful lumps under skin)

  Sorry, in progress, not accepting new patients

  This study is to evaluate the safety and efficacy of 2 dose levels of risankizumab in adult participants with moderate to severe Hidradenitis Suppurativa (HS). This study includes two treatment periods. In Period A, participants are randomized to receive either risankizumab dose A, dose B, or placebo. In Period B, participants who received risankizumab dose A or placebo during Period A, will receive risankizumab dose B. Participants who received risankizumab dose B in Period A will remain on that dose in Period B.

  at UC Davis

Last updated: November 9, 2020